Bernstein maintains Eli Lilly stock Outperform, $1,100 target
Bernstein analysts maintained their positive stance on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amidst a competitive ...
WST, GXIG, STVN poised to benefit from Abbott's CGM growth
KeyBanc highlighted WST, GXIG, and STVN as the main beneficiaries following robust demand in the Continuous Glucose ...